OLODATEROL HYDROCHLORIDE generics — when can they launch?
OLODATEROL HYDROCHLORIDE (OLODATEROL HYDROCHLORIDE) · · 8 active US patents · 0 expired
Where OLODATEROL HYDROCHLORIDE sits in the generic timeline
All listed Orange Book patents for OLODATEROL HYDROCHLORIDE have expired. Generic entry is permitted, and ANDA filers can launch without patent infringement risk. Hatch-Waxman exclusivity (NCE/ODE/PED) may still apply if recently approved.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Formulation — 4 patents
- Composition of Matter — 2 patents
- Other — 2 patents
Sample patent estate
Showing 6 of 8 active US patents. View full estate on the OLODATEROL HYDROCHLORIDE drug page →
-
This patent protects a locking-stressing-mechanism with a spring-actuated output drive device.USPTO title: Blocking device for a locking stressing mechanism having a spring-actuated output drive device
-
This patent protects a pharmaceutical composition containing the compound olodaterol hydrochloride, used to treat chronic obstructive pulmonary disease.USPTO title: Medicaments for the treatment of chronic obstructive pulmonary disease
-
This patent protects a pharmaceutical composition containing the compound olodaterol hydrochloride, used to treat chronic obstructive pulmonary disease.USPTO title: Medicaments for the treatment of chronic obstructive pulmonary disease
-
This patent protects a device for clamping a fluidic component in a holder using an elastomeric shaped part.USPTO title: Device for clamping a fluidic component
-
This patent protects a blocking device for a locking mechanism that uses a spring-actuated output drive device.USPTO title: Blocking device for a locking stressing mechanism having a spring-actuated output drive device
-
This patent protects a device for clamping a fluidic component in a holder using an elastomeric shaped part.USPTO title: Device for clamping a fluidic component
Sources
- FDA Orange Book — patents listed against OLODATEROL HYDROCHLORIDE (NDA filed 2014)
- OLODATEROL HYDROCHLORIDE drug profile — full patent estate, indications, clinical trials, pricing
- Patent cliff 2026 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on OLODATEROL HYDROCHLORIDE — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →